Drug Trial Radar · NCT04356664
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Mar 18, 2021
Primary completion
Jun 18, 2026
Study completion Jun 18, 2026
Sponsor
- Lead sponsor
- Hopital FochAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 36 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.
Conditions
- Endometriosis
- Adenomyosis
- Infertility, Female
Interventions
GnRH agonistDrug
One or two intramuscular injections of Decapeptyl 3 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical pregnancy rate in both groups at last visit ultrasoundTime frame: 3 months after frozen embryon transfer
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hopital Foch
Suresnes, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.